溶瘤生物科技 ONCY 深 沪
已收盘 01-30 16:00:00 美东时间
0.9807
-0.029
-2.90%
华盛通- 最 高1.04
- 今 开1.02
- 成交量 124.15万股
- 最 低 0.9699
- 昨 收 1.01
- 总市值 1.04亿
- 52周最高 1.51
- 市盈率 静 --
- 换手率 1.17%
- 52周最低 0.3258
- 委 比 92.13%
- 总股本 1.06亿
- 历史最高 6.037
- 量 比 0.87
- 振 幅 6.94%
- 历史最低 0.3258
- 每 手 1
- 风险率 0.28%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多$170B Patent Cliff Ignites Biotech Deal Wave: Late-Stage Platforms Command Premium
Issued on behalf of Oncolytics Biotech Inc. Equity-Insider.com News Commentary VANCOUVER, BC, Jan. 30, 2026 /PRNewswire/ -- The oncology sector is undergoing a massive capital rotation driv...
01-30 23:36
$668B Oncology Surge: 5 Platforms Cracking the Code on GI Tumors
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 30, 2026 /PRNewswire/ -- The global oncology sector is rocketing toward $668 billion in 2034[...
01-30 23:19
Oncolytics Biotech® Announces Results of Special Meeting of Shareholders
Oncolytics Biotech Inc. announced the results of its Special Meeting of Shareholders, where all resolutions were approved. The Continuance Resolution (85.21% for) authorizes the Company to move from Alberta to British Columbia. The Domestication Resolution (86.98% for) allows it to relocate to Nevada. The 2026 Incentive Award Plan Resolution (76.77% for) approves the new incentive plan, contingent on the completion of the Continuance and Domestic...
01-15 21:01
Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
01-13 22:50
Oncolytics Biotech Intends To Change Jurisdiction Of Incorporation To Nevada
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today provided additional context regarding its previously announced proposal to
01-09 22:07
Oncolytics Biotech Anticipates Final Action For Its Track 1 Prioritized Examination Patent Application With U.S. PTO In Q4
Oncolytics Biotech® Inc. (Nasdaq: ONCY) ("Oncolytics" or the "Company"), a clinical-stage immunotherapy company developing pelareorep, today provided an update on the status of its intellectual property ("IP")
01-08 22:09
How $594B in Precision Tech is Cracking the Metastatic Cancer Code
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, Jan. 7, 2026 /PRNewswire/ -- The global cancer drugs market is surging toward $594.3 billion by 2...
01-07 23:32
Smart Oncology: 5 Stocks Chasing the $317B Prize
Issued on behalf of Oncolytics Biotech Inc. USANewsGroup.com News Commentary VANCOUVER, BC, Dec. 31, 2025 /PRNewswire/ -- The precision oncology market surged to $139.4 billion in 2025 and i...
2025-12-31 20:25
Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443B
Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Dec. 16, 2025 /PRNewswire/ -- USANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors ...
2025-12-17 02:17
Oncolytics Biotech Announces Clinical And Translational Findings Supporting Development Of Pelareorep In Second-Line mCRC, Specifically In Patients With KRAS- MSS Disease
33% ORR achieved in second-line KRAS-mutant MSS colorectal cancer—triple historical response rates for Avastin + FOLFIRI of 6-11%Translational analysis shows pelareorep enhances KRAS-mutant–specific T-cell activity,
2025-12-16 22:06
